CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA

Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys, its trastuzumab biosimilar version.

Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission (EC).

This is CuraTeQ's fourth biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025 and Dyrupeg in June 2025. Dazublys, Zefylti, and Dyrupeg are also approved in the European Union.